--- title: "Efruxifermin | PepTracker Pro" description: "Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026)." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Efruxifermin", "description": "Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026).", "url": "https://peptrackerpro.com/peptides/efruxifermin", "lastReviewed": "2026-07-13", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Efruxifermin", "item": "https://peptrackerpro.com/peptides/efruxifermin" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People with MASH/NASH, advanced fibrosis, or compensated cirrhosis tracking non-incretin, liver-directed drug candidates.?", "acceptedAnswer": { "@type": "Answer", "text": "Efruxifermin is a research peptide studied in preclinical models. Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026)." } }, { "@type": "Question", "name": "Clinicians and researchers comparing FGF21 analogs (efruxifermin vs pegozafermin) and weighing them against incretin and other MASH mechanisms.?", "acceptedAnswer": { "@type": "Answer", "text": "Efruxifermin is a research peptide studied in preclinical models. Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026)." } }, { "@type": "Question", "name": "Patients and caregivers interested in whether a drug can reverse established MASH cirrhosis, not just slow it.?", "acceptedAnswer": { "@type": "Answer", "text": "Efruxifermin is a research peptide studied in preclinical models. Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026)." } }, { "@type": "Question", "name": "Investors and industry watchers following Akero Therapeutics and the competitive MASH and FGF21 drug race, including the Phase 3 SYNCHRONY readouts.?", "acceptedAnswer": { "@type": "Answer", "text": "Efruxifermin is a research peptide studied in preclinical models. Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026)." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Efruxifermin **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Efruxifermin Low Evidence Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026). Aliases Efruxifermin +6 more Evidence Low Evidence Last Updated 2026-07-13 Reading Time 6 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Why Researchers Study It](#why-researchers-study) 4. [Proposed Mechanisms](#proposed-mechanisms) 5. [Evidence Snapshot](#evidence-snapshot) 6. [Commonly Discussed Benefits](#benefits) 7. [Safety & Cautions](#safety) 8. [Comparisons](#comparisons) 9. [Calculator Tools](#calculator) 10. [Citations](#citations) ## What It Is Efruxifermin (EFX) is an investigational, once-weekly, subcutaneously injected analog of fibroblast growth factor 21 (FGF21), the endogenous hormone that helps the body respond to metabolic stress. Native FGF21 is secreted mainly by the liver and acts through FGF receptors and the co-receptor beta-Klotho in liver, adipose tissue, and the central nervous system to improve insulin sensitivity, increase fat oxidation, lower circulating triglycerides, and reduce hepatic fat, inflammation, and fibrosis - but it is cleared from the body within hours, making it impractical as a drug. Efruxifermin is engineered to overcome this: it is a bivalent Fc-FGF21 fusion protein in which two modified FGF21 sequences are fused to a human IgG1 Fc domain, an approach that both stabilizes the molecule and slows its clearance enough to allow once-weekly injection, while a set of point mutations preserves potent receptor activity. This Fc-fusion strategy is the key structural contrast with pegozafermin, the other leading FGF21 analog, which instead uses site-specific glycoPEGylation. Developed by Akero Therapeutics (the molecule originated at Amgen as AMG 876), efruxifermin has become one of the most advanced FGF21-pathway therapies and a central test of whether directly engaging FGF21 can not only cut liver fat but actually reverse fibrosis - and even established cirrhosis - in MASH. Its clinical program spans the full fibrosis spectrum, from pre-cirrhotic F2-F3 disease (BALANCED, HARMONY, and Phase 3 SYNCHRONY Histology) to compensated F4 cirrhosis (SYMMETRY and Phase 3 SYNCHRONY Outcomes), plus a large real-world safety study, SYNCHRONY Real-World. Also known as: Efruxifermin, EFX, AKR-001, AMG 876, Fc-FGF21 fusion protein, Akero FGF21 analog, efruxifermin (MASH) ## Regulatory Status ## Why Researchers Study It Efruxifermin is one of the two most advanced FGF21 analogs and, alongside pegozafermin, a decisive test of whether directly engaging the FGF21 metabolic pathway can reverse liver fibrosis - and even compensated cirrhosis - in MASH, the outcomes regulators care about most. Because it works through a mechanism entirely different from the GLP-1/GIP/glucagon incretin drugs, it is studied both as a standalone MASH therapy across the full fibrosis spectrum and as a potential future combination partner for incretin-based weight-loss agents. Its Fc-FGF21 fusion design versus pegozafermin's glycoPEGylation makes the two a closely watched head-to-head on how best to drug the FGF21 pathway, and Akero's Phase 3 SYNCHRONY readouts are viewed as a bellwether for the entire MASH field. ## Proposed Mechanisms - FGF21 receptor agonism: efruxifermin activates FGF receptor complexes (FGFR1c, FGFR2c, and FGFR3c) together with the co-receptor beta-Klotho in liver, adipose tissue, and other metabolic tissues, reproducing and amplifying the actions of native FGF21. - Direct hepatic effects: reduces hepatic de novo lipogenesis and liver fat, and drives anti-inflammatory and anti-fibrotic actions in the liver, aiming to reverse steatohepatitis and, in advanced disease, established fibrosis and cirrhosis. - Improved insulin sensitivity and lipid handling: enhances peripheral glucose uptake and fat oxidation and lowers circulating triglycerides while improving the cholesterol profile, targeting the metabolic drivers of MASH. - Adipose-tissue signaling: acts on fat to raise adiponectin and promote healthier lipid storage, part of the broader FGF21 metabolic program. - Fc-fusion half-life extension: fusing two FGF21 sequences to a human IgG1 Fc domain stabilizes the protein and slows clearance enough to allow once-weekly subcutaneous dosing while preserving receptor potency - a structural contrast with pegozafermin's glycoPEGylation approach. ## Evidence Snapshot Low Evidence Low Medium High Study Type Model Outcome Link RCT (human, Phase 2b - HARMONY, 96 weeks) Biopsy-confirmed F2-F3 (pre-cirrhotic) MASH; once-weekly subcutaneous efruxifermin 28 mg or 50 mg vs placebo across 41 US centers At least one-stage fibrosis improvement without worsening of MASH at week 96 in ~75% (50 mg) and ~46% (28 mg) vs ~24% placebo; near-complete disease reversal in roughly one-third of the 50 mg group, with improvements in liver injury and metabolic markers [Source](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(25\)01073-6/abstract) RCT (human, Phase 2b - SYMMETRY, 96 weeks) Compensated (F4) cirrhosis due to MASH; once-weekly subcutaneous efruxifermin 28 mg or 50 mg vs placebo Reversal of cirrhosis (>=1-stage fibrosis improvement to F3 or better) without worsening of MASH at week 96 in ~39% of 50 mg patients with paired biopsies vs ~15% placebo (p=0.009); ~29% in the intent-to-treat analysis counting missing biopsies as failures [Source](https://www.nejm.org/doi/full/10.1056/NEJMoa2502242) RCT (human, Phase 3 - SYNCHRONY program, ongoing) SYNCHRONY Histology (F2-F3 MASH), SYNCHRONY Outcomes (compensated F4 cirrhosis, initiated June 2024), and SYNCHRONY Real-World (non-invasively diagnosed MASH/MASLD, F1-F4, ~601 patients; once-weekly 50 mg vs placebo) Pivotal program designed to confirm fibrosis improvement, MASH resolution, cirrhosis reversal, and clinical outcomes; SYNCHRONY Real-World completed double-blind enrollment with safety/tolerability results expected in 2026 [Source](https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-completes-enrollment-double-blind-portion/) ## Commonly Discussed Benefits [metabolic dysfunction-associated steatohepatitis (MASH/NASH) - fibrosis improvement and MASH resolution in pre-cirrhotic F2-F3 disease (investigational)]()[reversal of compensated (F4) cirrhosis due to MASH without worsening of MASH (investigational; Phase 2b SYMMETRY, Phase 3 SYNCHRONY Outcomes)]()[reductions in liver fat (MRI-PDFF), liver enzymes, and non-invasive fibrosis biomarkers]()[improved insulin sensitivity, glycemic markers, and blood lipids (lower triglycerides, improved cholesterol profile)]()[convenient once-weekly subcutaneous dosing enabled by Fc-fusion half-life extension]() Researching Efruxifermin ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=efruxifermin) ## Safety & Cautions - Investigational and not approved: efruxifermin is in Phase 3 development for MASH across the fibrosis spectrum and is not available by prescription; its ability to improve fibrosis and clinical outcomes in the pivotal Phase 3 SYNCHRONY trials remains to be confirmed. - No self-sourcing: efruxifermin is a proprietary, engineered Fc-FGF21 fusion biologic studied only in controlled trials. Material sold online as 'efruxifermin', 'EFX', 'AKR-001', or 'FGF21' is not the clinical drug and cannot be assumed authentic, pure, or safe. - Gastrointestinal effects and appetite: the most commonly reported adverse effects in trials are diarrhea, nausea, and increased appetite, generally mild-to-moderate and transient. - FGF21-class considerations: agents in this class have been examined for possible effects on bone-turnover markers and other parameters; the long-term significance of these signals is still being studied. - Not a weight-loss or obesity drug: unlike the incretins, efruxifermin is being developed for liver disease (MASH), and it should not be conflated with GLP-1/GIP-based weight-loss therapies. ## Comparisons See how Efruxifermin compares to related peptides: [Efruxifermin vs Tirzepatide](/compare/efruxifermin-vs-tirzepatide) [Efruxifermin vs Survodutide](/compare/efruxifermin-vs-survodutide) [Efruxifermin vs Pemvidutide](/compare/efruxifermin-vs-pemvidutide) [Efruxifermin vs Efocipegtrutide](/compare/efruxifermin-vs-efocipegtrutide) [Efruxifermin vs Pegozafermin](/compare/efruxifermin-vs-pegozafermin) [Efruxifermin vs Efimosfermin Alfa](/compare/efruxifermin-vs-efimosfermin) [Efruxifermin vs Efinopegdutide](/compare/efruxifermin-vs-efinopegdutide) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Safety and efficacy of once-weekly efruxifermin versus placebo in MASH (HARMONY): 96-week results from a Phase 2b trial - The Lancet (August 2025) [PubMed](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(25\)01073-6/abstract) 2. \[2\] Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (SYMMETRY) - New England Journal of Medicine [PubMed](https://www.nejm.org/doi/full/10.1056/NEJMoa2502242) 3. \[3\] Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH [PubMed](https://www.biospace.com/akero-therapeutics-announces-initiation-of-phase-3-synchrony-outcomes-trial-of-efruxifermin-in-patients-with-compensated-cirrhosis-f4-due-to-mash) 4. \[4\] Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study - Akero Therapeutics [PubMed](https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-completes-enrollment-double-blind-portion/) 5. \[5\] Efruxifermin for MASH - Akero Therapeutics (mechanism and clinical program overview) [PubMed](https://akerotx.com/efruxifermin/) ### Keep researching in the app - Log Efruxifermin to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=efruxifermin) [Browse more peptides](/peptides) ## Related Peptides ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/survodutide) [\+ Compare](/compare?select=survodutide)[](https://app.peptrackerpro.com/?add=survodutide) ### Pemvidutide Medium Evidence A GLP-1/glucagon dual receptor agonist with FDA Breakthrough Therapy Designation for MASH, showing strong weight loss and liver benefits in Phase 2 trials. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Liver Health](/benefits/liver-health)[Metabolism](/benefits/metabolism) [View Details](/peptides/pemvidutide) [\+ Compare](/compare?select=pemvidutide)[](https://app.peptrackerpro.com/?add=pemvidutide) ### Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. [Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[Glycemic Control](/benefits/glycemic-control)[Metabolism](/benefits/metabolism) [View Details](/peptides/efocipegtrutide) [\+ Compare](/compare?select=efocipegtrutide)[](https://app.peptrackerpro.com/?add=efocipegtrutide) ### Pegozafermin Low Evidence Pegozafermin (development code BIO89-100) is an investigational, long-acting analog of fibroblast growth factor 21 (FGF21) being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and for severe hypertriglyceridemia (SHTG). Originally developed by 89bio and acquired by Roche in a deal announced in September 2025 (about $2.4 billion upfront and up to roughly $3.5 billion including a contingent value right), it uses site-specific glycoPEGylation to extend the very short half-life of native FGF21 to roughly 55-100 hours, enabling once-weekly or once-every-two-weeks subcutaneous dosing. FGF21 is a metabolic hormone that acts on liver, fat, and other tissues to improve insulin sensitivity, lower triglycerides, and exert direct anti-fibrotic and anti-inflammatory effects. In the Phase 2b ENLIVEN trial in biopsy-confirmed F2-F3 MASH, the 44 mg every-two-weeks dose produced at least a one-stage fibrosis improvement without worsening of MASH in about 27% of patients versus 7% on placebo, and MASH resolution without worsening of fibrosis in about 26% versus 2% on placebo, with benefits sustained through week 48. Pegozafermin holds FDA Breakthrough Therapy designation and EMA PRIME status for MASH and has advanced into the Phase 3 ENLIGHTEN program (ENLIGHTEN-Fibrosis in non-cirrhotic F2-F3 MASH and ENLIGHTEN-Cirrhosis in compensated F4 cirrhosis), plus the Phase 3 ENTRUST trial in SHTG. [metabolic dysfunction-associated steatohepatitis (MASH/NASH) - fibrosis improvement, MASH resolution, and reduced liver fat (investigational)]()[severe hypertriglyceridemia (SHTG) - large reductions in blood triglycerides (investigational; Phase 3 ENTRUST)]()[improved insulin sensitivity and glycemic markers]()[improvements in non-invasive markers of liver injury and fibrosis (liver fat by MRI-PDFF, liver enzymes, fibrosis biomarkers)]()+1 more [View Details](/peptides/pegozafermin) [\+ Compare](/compare?select=pegozafermin)[](https://app.peptrackerpro.com/?add=pegozafermin) ### Efimosfermin Alfa Low Evidence Efimosfermin alfa (development code BOS-580) is an investigational, long-acting, engineered analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by GSK - which acquired the molecule from Boston Pharmaceuticals in May 2025 for $1.2 billion upfront and up to $800 million in milestones (potential ~$2 billion total) - for steatotic liver disease, principally metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Its defining feature is a very long half-life engineered to allow once-monthly subcutaneous dosing - the least frequent schedule among the leading FGF21 analogs, contrasting with the once-weekly or every-two-weeks dosing of efruxifermin (an Fc-FGF21 fusion) and pegozafermin (a glycoPEGylated FGF21). Like the rest of the class, it activates FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho to cut liver fat, improve insulin sensitivity, lower triglycerides, and drive direct anti-inflammatory and anti-fibrotic effects in the liver. In a 24-week Phase 2 trial in biopsy-confirmed F2-F3 MASH, once-monthly efimosfermin achieved at least one-stage fibrosis improvement without worsening of MASH in about 45% of patients and MASH resolution without worsening of fibrosis in about 68%, both significantly better than placebo (published in The Lancet, 2025). It holds FDA Breakthrough Therapy designation and EMA PRIME (Priority Medicines) status for MASH, and has advanced into the Phase 3 ZENITH program (ZENITH-1 and ZENITH-2 in F2-F3 MASH), with a Phase 3 program in compensated (F4) MASH cirrhosis also underway; GSK has guided to a first potential launch around 2029. [metabolic dysfunction-associated steatohepatitis (MASH/NASH) - fibrosis improvement and MASH resolution in pre-cirrhotic F2-F3 disease (investigational)]()[reductions in liver fat (MRI-PDFF), liver enzymes, and non-invasive fibrosis biomarkers]()[improved insulin sensitivity, glycemic markers, and blood lipids (lower triglycerides, improved cholesterol profile)]()[potential treatment of compensated (F4) MASH cirrhosis (investigational; Phase 3 program underway)]()+1 more [View Details](/peptides/efimosfermin) [\+ Compare](/compare?select=efimosfermin)[](https://app.peptrackerpro.com/?add=efimosfermin) ### Efinopegdutide Medium Evidence Efinopegdutide (MK-6024, formerly HM12525A and JNJ-64565111) is an investigational once-weekly subcutaneous dual agonist of the GLP-1 and glucagon receptors being developed by Merck for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease. It is a synthetic oxyntomodulin-based peptide - a modified GLP-1/glucagon dual-agonist sequence conjugated to a human IgG4 Fc fragment through a 10 kDa polyethylene glycol linker using Hanmi Pharmaceutical's LAPSCovery half-life-extension platform, which stretches dosing to once weekly. The design pairs the GLP-1 arm (appetite suppression, glycemic control, weight loss) with a glucagon arm that raises energy expenditure and acts directly on the liver to burn hepatic fat - the feature that sets it apart from pure GLP-1 drugs. In the head-to-head Phase 2a trial in NAFLD (Journal of Hepatology, 2023), efinopegdutide 10 mg cut liver fat content by 72.7% at 24 weeks versus 42.3% for semaglutide 1 mg, with two-thirds of efinopegdutide recipients falling below the 5% liver-fat threshold that defines a normal liver. Merck holds FDA Fast Track designation for the MASH program and is running Phase 2b studies plus a dedicated trial in compensated cirrhosis due to steatohepatitis; the earlier type 2 diabetes and obesity indications were discontinued in favor of the liver focus. [metabolic-health](/benefits/metabolic-health)[Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[disease-modification](/benefits/disease-modification)+1 more [View Details](/peptides/efinopegdutide) [\+ Compare](/compare?select=efinopegdutide)[](https://app.peptrackerpro.com/?add=efinopegdutide) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.